Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
May 1, 2026
Manufacturing Industry Advisor
A New DOL Joint Employment Rule? What Franchisors Need to Know
On April 22, 2026, the U.S. Department of Labor's Wage and Hour Division published a proposed rule to establish a single, nationwide…
May 27, 2026
Events
ABA’s Qui Tam & Civil False Claims and Healthcare Fraud Institute 2026
Foley partner Lisa Noller, Chair of the Firm’s Litigation Department, will be speaking at the American Bar Association’s Qui Tam & Civil False Claims and Healthcare Fraud Institute in Washington, D.C. from May 27-28.
April 30, 2026
Foley Viewpoints
Sizing Up The 3-Way Battle For 'Iceman' IP Rights
Trademark rights in the U.S. arise from use in commerce, not from registration alone. The Lanham Act's first-to-use framework means that a party who can demonstrate earlier, continuous commercial use of a mark holds superior rights over a later filer. This principle is the backbone of Gervin's case against Williams.